<?xml version="1.0" encoding="UTF-8"?>
<p>Candidates selected for NHP AAV studies were first tested for expression and neutralization in mice 
 <italic>in vivo</italic> using AAV8. Mice were injected IM with 2.5 x 10
 <sup>10</sup> gc/animal (n = 1/mAb). All antibodies were detected in sera at high concentration and exhibited binding to SIVmac239 gp140 by week 8 (
 <xref ref-type="supplementary-material" rid="ppat.1007395.s003">S3A Fig</xref>). Transgene antibody neutralization capacity in serum was assayed to ensure proper function. ITS01, ITS06.02 and ITS11 demonstrated neutralization while ITS08 and ITS10 failed to neutralize (
 <xref ref-type="supplementary-material" rid="ppat.1007395.s003">S3B Fig</xref>). ITS01 and ITS06.02 were selected for advancement to NHP 
 <italic>in vivo</italic> testing based on these data to have one anti-CD4bs and one anti-V1 AAV construct. ITS11 was not selected given its poorer expression and lower potency than ITS06.02.
</p>
